Visita Medicitalia per info su Prof.ssa Paola Rogliani, Pneumologo. Trova telefono, indirizzo dove riceve, patologie trattate e curriculum.

Attenzione: l'iscritto non si collega da più di sei mesi, i dati potrebbero essere non aggiornati.

Prof.ssa Paola Rogliani

Pneumologo

Specialista in:

0 Consulti

0 Recensioni

Feed Rss Rss

Scheda vista 3.856 volte

0 News/Blog
0 Articoli
Indice di attività:
12% attività +12
0% attualità +0
0% socialità +0
Policlinico Tor Vergata

viale Oxford, 81 - 00100 Roma (RM) - Mappa

12.66287710000006 41.83073599999999

Vedi dettagli

Speciale Salute

Tutto sugli inalatori
04-03-2015 - Pneumologia
Visto 32.050 volte

Informazioni professionali

Laureata in Medicina e Chirurgia nel 1994 presso Università di Roma "Tor Vergata". Iscritta all'Ordine dei Medici di Roma.

Verifica dati su FNOMCeO.it »

Curriculum vitae

Paola Rogliani è Professore Associato in Malattie dell’Apparato Respiratorio (MED10), presso il Dipartimento di Medicina dei Sistemi dell’Università di Roma Tor Vergata e Direttore della UOC di Malattie dell’Apparato Respiratorio del Policlinico Tor Vergata; inoltre Direttore della scuola di specializzazione in “Malattie dell’Apparato Respiratorio”, Università di Roma Tor Vergata. Dopo la laurea con lode in Medicina e Chirurgia (1994)...

Leggi tutto

e la specializzazione in Malattie dell’Apparato Respiratorio (1998) ha effettuato un periodo di formazione post-specialistica di circa 4 anni presso la Pulmonary and Critical Care Medicine Branch e poi il Laboratrory of Molecular Immunology del NHLBI , NIH, Bethesda, USA. Al suo rientro si è dedicata alla cura e allo studio delle Pneumopatie Infiltrative Diffuse in particolare alla Fibrosi Polmonare Idiopatica (UIP) e negli ultimi anni alla cura e allo studio delle comorbilità associate alla BPCO. Gli studi della Prof.ssa Rogliani hanno permesso di identificare il ROSE, uno score multifattoriale utile per stratificare il rischio di malattia in pazienti affetti da fibrosi polmonare idiopatica, e rilevare precocemente la progressione rapida di malattia, fornendo indicazioni per la gestione di questa condizione mortale. (Eur Respir J. 2012); la caratterizzazione della fibrosi polmonare idiopatica associata all’enfisema (Respir Med 2008, Radiology 2010); le associazioni fra BPCO e/o asma e comorbilità utilizzando database di Medicina Generale nazionali (Respir Med. 2012, Eur Respir J. 2011); Identificazione di meccanismi/recettori coinvolti nella regolazione del tono bronco motore (Am J Respir Cell Mol Biol 2012) associata a comorbilità metaboliche quali il diabete (Acta Diabetol. 2014). E’ autore di oltre 90 lavori scientifici pubblicati su riviste internazionli indicizzate; Relatore e Moderatore a congressi nazionali e internazionali. Nel 2010 ha vinto il Premio Miglior ricercatore under 40 dell’ XI° Congresso Nazionale della Pneumologia - U.I.P. Membro del comitato editoriale della rivista internazionale “Pulmonary Pharmacology and Therapeutics”, “COPD Research and Practice” e della rivista nazionale “ARS Pneumologica”.
 
Pubblicazioni Ultimi 5 Anni (2010-2015)
 
       1)      Sergiacomi G, Bolacchi F, Cadioli M, Angeli ML, Fucci F, Crusco S, Rogliani P, Pezzuto G, Romeo F, Mariano E, Simonetti G. Combined pulmonary fibrosis and emphysema: 3D time-resolved MR angiographic evaluation of pulmonary arterial mean transit time and time to peak enhancement. Radiology. 2010 Feb;254(2):601-8.
       2)      Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J. 2011 Jul;38(1):42-9.
       3)      Matera MG, Calzetta L, Rogliani P, Bardaro F, Page CP, Cazzola M. Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi. Pulm Pharmacol Ther. 2011 Apr;24(2):221-6.
       4)      Cazzola M, Segreti A, Bettoncelli G, Calzetta L, Cricelli C, Pasqua F, Rogliani P. Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J. 2011 Sep;20(3):291-8.
       5)      Pompeo E, Rogliani P, Tacconi F, Dauri M, Saltini C, Novelli G, Mineo TC; Awake Thoracic Surgery Research Group. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg. 2012 Jan;143(1):47-54.e1.
       6)      Cazzola M, Calzetta L, Bettoncelli G, Cricelli C, Romeo F, Matera MG, Rogliani P. Cardiovascular disease in asthma and COPD: A population-based retrospective cross-sectional study. Respir Med. 2012 Feb;106(2):249-56.
       7)      Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012 Jul;40(1):101-9.
       8)      Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, Kanabar V, Matera MG. High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am J Respir Cell Mol Biol. 2012 Oct;47(4):509-16.
       9)      Cazzola M, Capuano A, Rogliani P, Matera MG. Bacterial lysates as a potentially effective approach in preventing acute exacerbation of copd. Curr Opin Pharmacol. 2012 Jun;12(3):300-8.
     10)     Matera MG, Calzetta L, Passeri D, Rogliani P, Orlandi A. Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity. Pulm Pharmacol Ther. 2012 Sep 21.
     11)     Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs. 2012 Oct;21(10):1489-501.
     12)     Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc). 2012 Dec;48(12):785-94.
     13)     Pompeo E, Rogliani P, Cristino B, Schillaci O, Novelli G, Saltini C. Awake Thoracoscopic Biopsy of Interstitial Lung Disease. Ann Thorac Surg. 2013 Feb;95(2):445-52.
     14)     Cazzola M, Segreti A, Stirpe E, Puxeddu E, Ora J, Rogliani P, Matera MG. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med. 2013 Jan;107(1):107-11.
     15)     Cazzola M, Segreti A, Calzetta L, Rogliani P. Comorbidities of asthma: current knowledge and future research needs. Curr Opin Pulm Med. 2013 Jan;19(1):36-41-
     16)     Rogliani P, Calzetta L, Rendina EA, Massullo D, Dauri M, Rinaldi B, Capuano A, Matera MG. The influence of propofol, remifentanil and lidocaine on the tone of human bronchial smooth muscle. Pulm Pharmacol Ther. 2013 Jun;26(3):325-
     17)     Cazzola M, Page CP, Rogliani P, Matera MG. β2-Agonist Therapy in Lung Disease. Am J Respir Crit Care Med. 2013 Apr 1;187(7):690-6.
     18)     Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013 Apr 8.
     19)     Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med. 2013 Jun;107(6):848-53.
     20)     Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Apr;14(6):775-81.
     21)     Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med. 2013 Jun;107(6):848-53.
     22)     Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J Thorac Cardiovasc Surg. 2013 Aug;146(2):495-7.
     23)     Calzetta L, Passeri D, Kanabar V, Rogliani P, Page C, Cazzola M, Matera MG,Orlandi A. Brain Natriuretic Peptide Protects Against Hyperreactivityof Human Asthmatic Airway Smooth Muscle via an Epithelial Cell DependentMechanism. Am J Respir Cell Mol Biol. 2013 Sep 27.
     24)     Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013 Sep;346(3):414-23.
     25)     Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. Respir Med. 2013 Sep;107(9):1417-22.
     26)     Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respir Med. 2013 Nov 5.
     27)     Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respir Med. 2013 Dec;107(12):2014-21.
     28)     Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Dec;14(18):2489-99.
     29)     Segreti A, Fiori E, Calzetta L, Sabatini M, Segreti V, Rogliani P, Cazzola M. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013 Dec;26(6):630-4.
     30)     Cazzola M, Rogliani P, Ruggeri P, Segreti A, Proietto A, Picciolo S, Matera MG. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD. Respir Med. 2013 Jun;107(6):848-53.
     31)     Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Apr;14(6):775-81.
     32)     Pompeo E, Dauri M; Awake Thoracic Surgery Research Group. Is there any benefit in using awake anesthesia with thoracic epidural in thoracoscopic talc pleurodesis? J Thorac Cardiovasc Surg. 2013 Aug;146(2):495-7.
     33)     Calzetta L, Page CP, Spina D, Cazzola M, Rogliani P, Facciolo F, Matera MG. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther. 2013 Sep;346(3):414-23.
     34)     Cazzola M, Calzetta L, Lauro D, Bettoncelli G, Cricelli C, Di Daniele N, Rogliani P. Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit. Respir Med. 2013 Sep;107(9):1417-22.
 
     35)     Ora J, Calzetta L, Pezzuto G, Senis L, Paone G, Mari A, Portalone S, Rogliani P, Puxeddu E, Saltini C. A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD. Respir Med. 2013 Dec;107(12):2014-21.
     36)     Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2013 Dec;14(18):2489-99
     37)     Rogliani P, Ora J, Ciaprini C, Senis L, Stirpe E, Cazzola M. Effect of indacaterol on arterial blood gases in patients suffering from acute exacerbation of COPD. Respir Med. 2013 Nov 5.
     38)     Matera MG, Calzetta L, Rogliani P, Cesario A, Cazzola M. New Treatments for COPD in the Elderly. Curr Pharm Des. 2014 Mar 14
     39)     Matera MG, Rogliani P, Cazzola M. Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2014 May;15(7):961-77
     40)     Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 2014 Apr 13
     41)     Calzetta L, Rogliani P, Cazzola M, Matera MG. Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond. Expert Opin Drug Discov. 2014 Jun;9(6):595-607.Epub 2014 Apr 22.
     42)     Segreti A, Stirpe E, Rogliani P, Cazzola M. Defining phenotypes in COPD: an aid to personalized healthcare. Mol Diagn Ther. 2014 Aug;18(4):381-
     43)     Cazzola M, Calzetta L, Segreti A, Facciolo F, Rogliani P, Matera MG. Translational Study Searching for Synergy between Glycopyrronium and Indacaterol. COPD. 2014 Sep 15
     44)     Matera MG, Rogliani P, Calzetta L, Cazzola M. Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold? Drugs. 2014 Oct 10.
     45)     Segreti A, Calzetta L, Rogliani P, Cazzola M. Umeclidinium for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2014 Oct 14:1-7.
     46)     Matera MG, Rogliani P, Rinaldi B, Cazzola M. Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015 Jan;8(1):35-41.
     47)     Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 Jan;16(1):107-15.
     48)     Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, Matera MG. Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol. 2014 Dec 15;745:135-43
     49)     Lipsi R, Rogliani P, Calzetta L, Segreti A, Cazzola M. The clinical use of regenerative therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2014 Dec 12;9:1389-1396. eCollection 2014.
     50)     Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015 Jan 5:1-9.
     51)     Rogliani P, Calzetta L, Ora J, Matera MG. Canakinumab for the treatment of chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015 Apr;31:15-27.
     52)     Matera MG, Rogliani P, Cazzola M. QVA149(indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015 May;16(7):1079-90.
     53)     Calzetta L, Cazzola M, Page CP, Rogliani P, Facciolo F, Matera MG. Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulm Pharmacol Ther. 2015 Apr 18.
     54)     Calzetta L, Luongo L, Cazzola M, Page C, Rogliani P, Facciolo F, Maione S, Capuano A, Rinaldi B, Matera MG. Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sci. 2015 Apr 24.
     55)     Rogliani P, Calzetta L, Ora J, Lipsi R, Segreti A, Matera MG, Cazzola M. Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi. Eur J Pharmacol. 2015 May 5
     56)     Cazzola M, Rogliani P, Sanduzzi A, Matera MG. Influence of ethnicity on response to asthma drugs. Expert Opin Drug Metab Toxicol. 2015 Jul;11(7):1089-97.
     57)     Ricciardolo FL, Blasi F, Centanni S, Rogliani P. Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma. Pulm Pharmacol Ther. 2015 May 23.
     58)     Pompeo E, Rogliani P, Palombi L, Orlandi A, Cristino B, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). The complex care of severe emphysema: role of awake lung volume reduction surgery. Ann Transl Med. 2015 May;3(8):108.
     59)     Pompeo E, Cristino B, Rogliani P, Dauri M; Awake Thoracic Surgery Research Group (ATSRG). Urgent awake thoracoscopic treatment of retained haemothorax associated with respiratory failure. Ann Transl Med. 2015 May;3(8):112.
     60)     Cazzola M, Calzetta L, Matera MG, Muscoli S, Rogliani P, Romeo F. Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients. Respir Med. 2015 Jun 22.
     61)     Cazzola M, Rogliani P, Matera MG. Cardiovascular disease in patients withCOPD. Lancet Respir Med. 2015 Jul 21.
     62)     Basello K, Pacifici F, Capuani B, Pastore D, Lombardo M, Ferrelli F, Coppola A, Donadel G, Arriga R, Sconocchia G, Bellia A, Rogliani P, Federici M, Sbraccia P, Lauro D, Della-Morte D. Serum- and Glucocorticoid-Inducible Kinase (SGK)1 delay the onset of Endothelial Senescence by Directly Interacting with hTERT. Rejuvenation Res. 2015 Jul 31
     63)     Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Drugs Today (Barc). 2015 Aug;51(8):469-78.
     64)     Cazzola M, Calzetta L, Ora J, Puxeddu E, Rogliani P, Matera MG. Searching for the synergistic effect between aclidinium and formoterol: From bench to bedside. Respir Med. 2015 Aug 13.
     65)     Cazzola M, Coppola A, Rogliani P, Matera MG. Novel glucocorticoid receptor agonists in the treatment of asthma. Expert Opin Investig Drugs. 2015 Aug 21:1-10
     66)     Cazzola M, Rogliani P, Ora J, Matera MG. Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease. Expert Rev Clin Pharmacol. 2015 Sep;8(5):529-39.
     67)     Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Gabriella Matera M. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015 Sep;24(137):451-61.
     68)     Cazzola M, Rogliani P, Matera MG. Escalation and De-escalation of Therapy in COPD: Myths, Realities and Perspectives. Drugs. 2015 Sep;75(14):1575-85.
     69)     Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Gabriella Matera M. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015 Sep;24(137):451-61.
     70)     Rogliani P, Matera MG, Cazzola M. Fluticasone furoate/vilanterol combination for the treatment of COPD and asthma. Drugs Today (Barc). 2015 Aug;51(8):469-78.
 

Sito web

Scheda personale

Attività su Medicitalia

La Prof.ssa Paola Rogliani è specialista di medicitalia.it dal 2015.